Release Date: 23-Jan-2025
CTX 009, also known as Tovecimig, is a bispecific antibody being developed by TRIGR Therapeutics, a subsidiary of Compass Therapeutics, for the treatment of solid tumors, including biliary cancer and colorectal cancer. This innovative antibody targets two key factors involved in tumor angiogenesisandmdash;vascular endothelial growth factor A (VEGF-A) and delta-like canonical notch ligand 4 (DLL4). Both VEGF-A and DLL4 are overexpressed in various cancers and play significant roles in the growth of blood vessels that supply tumors, a process known as angiogenesis. By targeting both of these factors, CTX 009 aims to inhibit tumor blood vessel formation and disrupt the tumor’s ability to grow and spread.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
CTX 009 is developed using ABL’s proprietary bispecific antibody technology, Grabody-A, which allows for the simultaneous targeting of VEGF-A and DLL4. VEGF-A is a well-known driver of angiogenesis, promoting the growth of new blood vessels that nourish tumors, while DLL4 is a ligand that activates the Notch signaling pathway, which also plays a critical role in the development of blood vessels within tumors. By blocking both pathways, CTX 009 aims to provide a more effective approach to tumor vascularization inhibition compared to therapies targeting just one of these factors. This dual targeting could improve treatment outcomes by addressing multiple aspects of tumor blood vessel formation.
Currently, CTX 009 is undergoing Phase 2/3 clinical trials for biliary tract cancer, with top-line data expected in Q1 2025. These trials are evaluating its safety and efficacy as a second-line treatment for patients with advanced biliary cancer. The dual angiogenesis inhibition offered by CTX 009 holds promise for treating a range of cancers, and the results from ongoing clinical trials will help determine its potential as a new therapeutic option for patients with difficult-to-treat solid tumors.